Imagion Biosystems is pleased to provide an update on its progress and plans for manufacturing of its proprietary nanoparticle formulation in advance of the first in human study currently planned for mid-2020.
Read the update.
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal